

Request for Prior Authorization ANTIEMETIC-5HT3 RECEPTOR ANTAGONISTS/ SUBSTANCE P NEUROKININ PRODUCTS

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID # Pa						#			Pa	Patient name		DOB	
							1						
Patient address													
Provider NPI									Prescriber name		Phone		
Prescriber address												Fax	
Pharmacy name Ad									A	ddress	Phone		
-													
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.													
Pharmacy NPI										Pharmacy fax NDC			
						1							

Prior authorization is required for preferred Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin medications for quantities exceeding the dosage limits provided in parentheses. Payment for Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents beyond this limit will be considered on an individual basis after review of submitted documentation.

Prior authorization will be required for all non-preferred Antiemetic-5HT3 Receptor Antagonists/ Substance P Neurokinin medications beginning the first day of therapy. Payment for non-preferred medications will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent in this class. Note: Aprepitant (Emend®) will only be payable when used in combination with other antiemetic agents (5-HT3 medication and dexamethasone) for patients receiving highly emetogenic cancer chemotherapy.

Preferred □ Emend 80mg capsules (8)

Non Preferred

- □ Akynzeo (2)
 - □ Anzemet 50mg & 100mg tablets (5)
- □ Anzemet 100mg/5ml (4 vials)
- □ Anzemet 12.5mg/0.625ml (8 ampules)
- □ Ondansetron 2mg/mL (4 20mL vials) □ Aprepitant
- □ Ondansetron 2mg/mL (8 2mL vials) □ Emend Oral Suspension
 - □ Granisetron 1mg tablets (8)
- Ondansetron ODT 4mg tablets (60)
 Ondansetron ODT 8mg tablets (60)
- Ondansetron oral solution 4mg/5mL (50mL/month)

□ Emend 125mg capsules (4)

□ Ondansetron 4mg tablets (60)

□ Ondansetron 8mg tablets (60)

Sancuso patch

	Strength	Dosage Instructions	Quantity	Days Supply	
Diagnosis:					

Medical reasoning for therapy exceeding dosage limits: _

Reason for use of Non-Preferred drug requiring prior approval:_ Attach lab results and other documentation as necessary.

· ······,							
Prescriber signature (Must match prescriber listed above.)	Date of submission						
IMPORTANT NOTE: In evaluating requests for prior authorization, the consultant will consider the treatment from the standpoint of							
medical necessity only. If approval of this request is granted, this does not indicate that							
It is the responsibility of the provider who initiates the request for prior authorization to e	stablish by inspection of the member's Medicaid						
eligibility card and, if necessary, by contact with the county Department of Health and H	luman Services, that the member continues to be						
eligible for Medicaid.							